Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

How doctors choose medications to treat type 2 diabetes: a national survey of specialists and academic generalists.

Grant RW, Wexler DJ, Watson AJ, Lester WT, Cagliero E, Campbell EG, Nathan DM.

Diabetes Care. 2007 Jun;30(6):1448-53. Epub 2007 Mar 2.

2.

Managing type 2 diabetes: going beyond glycemic control.

Stolar MW, Hoogwerf BJ, Gorshow SM, Boyle PJ, Wales DO.

J Manag Care Pharm. 2008 Jun;14(5 Suppl B):s2-19.

PMID:
18597582
3.

Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians?

Shah BR, Hux JE, Laupacis A, Zinman B, van Walraven C.

Diabetes Care. 2005 Mar;28(3):600-6.

PMID:
15735195
4.

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control.

Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, Handelsman Y, Horton ES, Lebovitz H, Levy P, Moghissi ES, Schwartz SS.

Endocr Pract. 2009 Sep-Oct;15(6):540-59. Erratum in: Endocr Pract. 2009 Nov-Dec;15(7):768-70.

PMID:
19858063
5.

The evaluation of clinical and cost outcomes associated with earlier initiation of insulin in patients with type 2 diabetes mellitus.

Smolen HJ, Murphy DR, Gahn JC, Yu X, Curtis BH.

J Manag Care Spec Pharm. 2014 Sep;20(9):968-84.

6.
7.

Relational coordination amongst health professionals involved in insulin initiation for people with type 2 diabetes in general practice: an exploratory survey.

Manski-Nankervis JA, Blackberry I, Young D, O'Neal D, Patterson E, Furler J.

BMC Health Serv Res. 2014 Nov 1;14:515. doi: 10.1186/s12913-014-0515-3.

8.

Trends in the prescription of anti-diabetic medications in the United Kingdom: a population-based analysis.

Filion KB, Joseph L, Boivin JF, Suissa S, Brophy JM.

Pharmacoepidemiol Drug Saf. 2009 Oct;18(10):973-6. doi: 10.1002/pds.1802.

PMID:
19621344
9.

Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study.

Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM.

Diabet Med. 2012 May;29(5):682-9. doi: 10.1111/j.1464-5491.2012.03605.x.

10.

Use of an Electronic Medical Record (EMR) to Identify Glycemic Intensification Strategies in Type 2 Diabetes.

Korytkowski MT, Brooks M, Lombardero M, DeAlmeida D, Kanter J, Magaji V, Orchard T, Siminerio L.

J Diabetes Sci Technol. 2015 May;9(3):593-601. doi: 10.1177/1932296814564183. Epub 2014 Dec 18.

11.

Oral antidiabetic agents: current role in type 2 diabetes mellitus.

Krentz AJ, Bailey CJ.

Drugs. 2005;65(3):385-411. Review.

PMID:
15669880
12.
13.

Does availability of AIR insulin increase insulin use and improve glycemic control in patients with type 2 diabetes?

Bergenstal RM, Freemantle N, Leyk M, Cutler GB Jr, Hayes RP, Muchmore DB.

Diabetes Technol Ther. 2009 Sep;11 Suppl 2:S45-52. doi: 10.1089/dia.2009.0028.

PMID:
19772448
14.

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.

Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG; GWAA Study Group.

Ann Intern Med. 2005 Oct 18;143(8):559-69.

PMID:
16230722
15.

The ARMS-D out performs the SDSCA, but both are reliable, valid, and predict glycemic control.

Mayberry LS, Gonzalez JS, Wallston KA, Kripalani S, Osborn CY.

Diabetes Res Clin Pract. 2013 Nov;102(2):96-104. doi: 10.1016/j.diabres.2013.09.010. Epub 2013 Sep 26.

16.

[Optimised glycaemic control and dose titration with insulin glargine (Lantus) by general practitioners in Switzerland: results of the OPTI-LAN Postmarketing Study].

Spirk D, Lareida J, Scheidegger K, Diem P.

Praxis (Bern 1994). 2009 Mar 18;98(6):315-20. doi: 10.1024/1661-8157.98.6.315. German.

PMID:
19291638
17.

Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States.

Koro CE, Lee BH, Bowlin SJ.

Clin Ther. 2009 Nov;31(11):2608-17. doi: 10.1016/j.clinthera.2009.10.020.

PMID:
20110005
18.

Effect of patients' risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus.

Vijan S, Sussman JB, Yudkin JS, Hayward RA.

JAMA Intern Med. 2014 Aug;174(8):1227-34. doi: 10.1001/jamainternmed.2014.2894.

19.

Empirical validation of the information-motivation-behavioral skills model of diabetes medication adherence: a framework for intervention.

Mayberry LS, Osborn CY.

Diabetes Care. 2014;37(5):1246-53. doi: 10.2337/dc13-1828. Epub 2014 Mar 5.

20.

Randomized controlled trial of clinical pharmacy management of patients with type 2 diabetes in an outpatient diabetes clinic in Jordan.

Jarab AS, Alqudah SG, Mukattash TL, Shattat G, Al-Qirim T.

J Manag Care Pharm. 2012 Sep;18(7):516-26.

Supplemental Content

Support Center